There aren’t many companies that can land the biggest government contract in their history, watch their order book swell past the $2 billion mark, and still see their share price cut by roughly a third in a single month. Rocket Lab has managed exactly that — and the disconnect between what the business is doing and what the stock is saying has become the defining feature of the trade.
The whipsaw action has been brutal. After a 30-day slide that erased more than 33 percent of the company’s value, shares jumped 5.37 percent on Friday to €58.90, clawing back a slice of those losses. That bounce followed an even sharper single-day move earlier in the week, when the stock surged 9.18 percent to €55.90 on Thursday. The trigger for the Friday rally: a $266 million contract from the US Space Force covering twelve suborbital launches, with options for up to six more. The award — the largest government deal in company history — represents nearly 39 percent of Rocket Lab’s trailing twelve-month revenue.
The Thursday rebound had a different catalyst. Rocket Lab announced a multi-launch agreement with Japanese satellite operator iQPS, covering three missions aboard the Electron rocket. It’s the third major order from iQPS within a year, and it pushes the total number of contracted Electron missions to eighteen. The new flights are slated to lift off from Launch Complex 1 in late 2027.
The Market Is Pricing Something Else
That the stock responded positively to operational news suggests investors aren’t punishing the underlying business. What they are punishing is the structure of the company’s biggest strategic bet to date.
On June 29, Rocket Lab unveiled plans to acquire satellite operator Iridium Communications in a deal valued at roughly $8 billion. Iridium shareholders are set to receive $54 per share — half in cash, half in Rocket Lab stock via an exchange ratio protected by a collar mechanism. That collar is the source of the recent volatility. With Rocket Lab’s share price under pressure, the market has been wrestling with dilution risk and financing uncertainty rather than questioning the health of the launch business.
The broader sector hasn’t helped. Space stocks have cooled across the board, with SpaceX itself roughly halving from its post-IPO peak in June.
Should investors sell immediately? Or is it worth buying Rocket Lab?
A Split Between the Chart and the Street
Wall Street, for its part, remains conspicuously bullish. The average analyst price target sits at €99.32 — implying upside of nearly 69 percent from current levels. A separate survey of 17 analysts puts the consensus target at $114.33, roughly 79 percent above where the stock trades. Either way, the gap between the chart and the Street is unusually wide.
Recent analyst moves skew positive. Bank of America raised its target to $115 after the Space Force announcement, Roth Capital and Citizens both moved to $130, and New Street Research initiated coverage with a Street-high $150 target. Citizens analyst Trevor Walsh framed the Iridium deal as a significant accelerant for Rocket Lab’s push into higher-value space applications, creating a vertically integrated platform. KGI Securities upgraded the stock to “Outperform” with a $107 target on July 27, while Piper Sandler started coverage with a “Neutral” rating and $83 target on July 16.
The bull case rests on fundamentals that are hard to dismiss. Iridium generates consistent profits and produced free cash flow of just under $300 million in 2025. Rocket Lab closed 2025 with $602 million in revenue and entered the first quarter of 2026 with a backlog exceeding $2 billion. For believers, the current discount represents mispricing rather than a fair reassessment of risk.
The Wildcard Nobody Can Price
Beyond the Iridium noise sits the Neutron rocket program — equal parts opportunity and risk. Management remains committed to a fourth-quarter 2026 target for the vehicle’s first flight. Success would mark a direct challenge to SpaceX’s dominance in the launch market. Tellingly, the Neutron manifest is filling up fast: five commercial missions are now booked despite the fact that the rocket hasn’t flown a single time. Customers are betting on execution before proof of concept.
The next major checkpoint arrives August 10, 2026, when Rocket Lab reports second-quarter earnings. Investors will be watching two things closely: the outlook for the core business and progress on integrating Iridium.
With annualized volatility approaching 98 percent, this is a stock that will keep whipsawing momentum traders in both directions. But the underlying picture — a record defense contract, a $2 billion backlog, and an acquisition that should be accretive despite its convoluted structure — doesn’t resemble a shrinking enterprise. The gap between the current price and what analysts see looks less like a fair assessment of risk and more like a market that’s struggling to model a deal it hasn’t fully digested yet. Those gaps tend to close once the financing picture becomes clearer.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 31 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 31.
Rocket Lab: Buy or sell? Read more here...
